{"id":19374,"date":"2023-05-05T10:13:00","date_gmt":"2023-05-05T10:13:00","guid":{"rendered":"https:\/\/clinlabint.com\/?p=19374"},"modified":"2023-05-05T10:13:51","modified_gmt":"2023-05-05T10:13:51","slug":"gyros-protein-technologies-introduces-gyrolab-generic-cyno-ada-kit-reagents-to-support-pre-clinical-immunogenicity-assessment","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/gyros-protein-technologies-introduces-gyrolab-generic-cyno-ada-kit-reagents-to-support-pre-clinical-immunogenicity-assessment\/","title":{"rendered":"Gyros Protein Technologies introduces Gyrolab Generic Cyno ADA Kit Reagents to support pre-clinical immunogenicity assessment"},"content":{"rendered":"<div id='av_section_1'  class='avia-section main_color avia-section-default avia-no-border-styling  avia-bg-style-scroll  avia-builder-el-0  avia-builder-el-no-sibling   container_wrap fullsize' style=' '  ><div class='container' ><main  role=\"main\" itemprop=\"mainContentOfPage\"  class='template-page content  av-content-full alpha units'><div class='post-entry post-entry-type-page post-entry-19374'><div class='entry-content-wrapper clearfix'>\n<div class=\"flex_column av_one_fifth  av-hide-on-mobile  flex_column_div av-zero-column-padding first  avia-builder-el-1  el_before_av_three_fifth  avia-builder-el-first  \" style='border-radius:0px; '><section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><p style=\"text-align: center\"><!--Begin ClixTrac.com Banner Code -->\r\n<a href=\"https:\/\/clixtrac.com\/goto\/?311442\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" src=\"https:\/\/clixtrac.com\/banner\/311442.jpg\" alt=\"Bio-Rad - Preparing for a Stress-free QC Audit\" title=\"Bio-Rad - Preparing for a Stress-free QC Audit\" border=\"0\" \/><\/a>\r\n<!--End ClixTrac.com Banner Code --><\/p>\n<\/div><\/section><\/div><div class=\"flex_column av_three_fifth  flex_column_div av-zero-column-padding   avia-builder-el-3  el_after_av_one_fifth  el_before_av_one_fifth  \" style='border-radius:0px; '><section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><p style=\"text-align: center\"><\/p>\n<\/div><\/section><br \/>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><header class=\"entry-content-header\"><h1 class=\"post-title entry-title\" itemprop=\"headline\">Gyros Protein Technologies introduces Gyrolab Generic Cyno ADA Kit Reagents to support pre-clinical immunogenicity assessment<\/h1><span class=\"post-meta-infos\">\/ <span class=\"blog-categories minor-meta\">in <a href=\"https:\/\/clinlabint.com\/e-news\/\" rel=\"tag\">E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section><br \/>\n<div  class='avia-image-container  av-styling-    avia-builder-el-6  el_after_av_textblock  el_before_av_textblock  avia-align-center '  itemprop=\"image\" itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/ImageObject\"  ><div class='avia-image-container-inner'><div class='avia-image-overlay-wrap'><img decoding=\"async\" class=\"avia_image\" src=\"https:\/\/clinlabint.com\/wp-content\/uploads\/sites\/2\/2023\/05\/image001.png\" alt=\"\" title=\"image001\" height=\"66\" width=\"300\" itemprop=\"thumbnailUrl\"><\/div><\/div><\/div><br \/>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><ul>\n<li><em>Ready-to-use kit expands range of bioanalysis kits, and enables generic detection of immune complexes in cyno samples<\/em><\/li>\n<\/ul>\n<p><!--more--><\/p>\n<p>Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents and a pioneer in automated nanoliter-scale immunoassays, today announced the introduction of Gyrolab<sup>\u00ae<\/sup> Generic Cyno Anti-Drug Antibodies (ADA) Kit Reagents, for the detection of circulating immune complexes of human IgG with cyno anti-human IgG. The new ready-to-use kit reagents streamline pre-clinical development of antibody-based therapeutics, enabling immunogenicity screening of drug candidates without the need for drug-specific ADA assay development.<\/p>\n<p>The new kit expedites bioanalysis by removing the need for assay development and optimization across molecules to provide robust, reproducible, reliable data from nanoliter sample volumes. This is beneficial when ADA assessment is evaluated in pre-clinical animal models where sample volume may be limited.<\/p>\n<p>Detecting and monitoring ADA is essential throughout drug development, in particular during the discovery stage, where multiple early-stage candidates are evaluated in parallel. During non-clinical studies, ADA monitoring is critical in understanding unexpected clearance profiles and safety or efficacy issues caused by formation of immune complexes.<\/p>\n<p>The new bioanalysis kit is optimized for use on all Gyrolab systems and complements the Company\u2019s existing portfolio of ready-to-use kits and solutions for pharmacokinetics and toxicokinetics, while expanding the utility of the Gyrolab platform into drug screening and preclinical phases of development. Automation with Gyrolab systems reduces variability due to manual intervention and speeds up workflows by generating 96 data points within 80 minutes, helping to speed the development of novel therapeutics. Additionally, the Gyrolab platform supports the development of drug-specific ADA assays in the later stages of drug development, using automated acid dissociation in the Gyrolab Mixing CD 96 and the dedicated Gyrolab ADA Software, enabling immunogenicity assessment all the way from discovery to every phase of process development.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>Mark Vossenaar, General Manager, Biopharmaceutical Development Division, Gyros Protein Technologies, commented: <\/strong><em>\u201cThe introduction of the Gyrolab Generic Cyno ADA Kit Reagents is another valuable addition to our extensive portfolio of ready-to-use kits and solutions. Expanding the utility of our platform into drug screening and preclinical development will enable researchers to maximize performance and productivity, which will ultimately reduce the time neded to develop novel antibody-based therapies.\u201d<\/em><\/p>\n<p><em>\u00a0<\/em><\/p>\n<p>For more information: <a href=\"http:\/\/www.gyrosproteintechnologies.com\/immunoassays\/products\/gyrolab-generic-cyno-ada-kit-reagents\" target=\"_blank\" rel=\"noopener\">www.gyrosproteintechnologies.com\/immunoassays\/products\/gyrolab-generic-cyno-ada-kit-reagents<\/a><\/p>\n<\/div><\/section><br \/>\n<div  class='avia-image-container  av-styling-    avia-builder-el-8  el_after_av_textblock  el_before_av_social_share  avia-align-center '  itemprop=\"image\" itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/ImageObject\"  ><div class='avia-image-container-inner'><div class='avia-image-overlay-wrap'><img decoding=\"async\" class=\"avia_image\" src=\"https:\/\/clinlabint.com\/wp-content\/uploads\/sites\/2\/2023\/05\/image002.jpg\" alt=\"\" title=\"image002\" height=\"144\" width=\"214\" itemprop=\"thumbnailUrl\"><\/div><\/div><\/div><br \/>\n<div  class='av-social-sharing-box  avia-builder-el-9  el_after_av_image  avia-builder-el-last  av-social-sharing-box-minimal '><div class='av-share-box'><h5 class='av-share-link-description av-no-toc '>Share this<\/h5><ul class='av-share-box-list noLightbox'><li class='av-share-link av-social-link-facebook' ><a target=\"_blank\" aria-label=\"Share on Facebook\" href=\"https:\/\/www.facebook.com\/sharer.php?u=https:\/\/clinlabint.com\/gyros-protein-technologies-introduces-gyrolab-generic-cyno-ada-kit-reagents-to-support-pre-clinical-immunogenicity-assessment\/&#038;t=Gyros%20Protein%20Technologies%20introduces%20Gyrolab%20Generic%20Cyno%20ADA%20Kit%20Reagents%20to%20support%20pre-clinical%20immunogenicity%20assessment\" aria-hidden=\"false\" data-av_icon=\"\ue8f3\" data-av_iconfont=\"entypo-fontello\" title=\"\" data-avia-related-tooltip=\"Share on Facebook\" rel=\"noopener\"><span class='avia_hidden_link_text'>Share on Facebook<\/span><\/a><\/li><li class='av-share-link av-social-link-twitter' ><a target=\"_blank\" aria-label=\"Share on Twitter\" href=\"https:\/\/twitter.com\/share?text=Gyros%20Protein%20Technologies%20introduces%20Gyrolab%20Generic%20Cyno%20ADA%20Kit%20Reagents%20to%20support%20pre-clinical%20immunogenicity%20assessment&#038;url=https:\/\/clinlabint.com\/?p=19374\" aria-hidden=\"false\" data-av_icon=\"\ue8f1\" data-av_iconfont=\"entypo-fontello\" title=\"\" data-avia-related-tooltip=\"Share on Twitter\" rel=\"noopener\"><span class='avia_hidden_link_text'>Share on Twitter<\/span><\/a><\/li><li class='av-share-link av-social-link-whatsapp' ><a target=\"_blank\" aria-label=\"Share on WhatsApp\" href=\"https:\/\/api.whatsapp.com\/send?text=https:\/\/clinlabint.com\/gyros-protein-technologies-introduces-gyrolab-generic-cyno-ada-kit-reagents-to-support-pre-clinical-immunogenicity-assessment\/\" aria-hidden=\"false\" data-av_icon=\"\uf232\" data-av_iconfont=\"entypo-fontello\" title=\"\" data-avia-related-tooltip=\"Share on WhatsApp\" rel=\"noopener\"><span class='avia_hidden_link_text'>Share on WhatsApp<\/span><\/a><\/li><li class='av-share-link av-social-link-linkedin' ><a target=\"_blank\" aria-label=\"Share on LinkedIn\" href=\"https:\/\/linkedin.com\/shareArticle?mini=true&#038;title=Gyros%20Protein%20Technologies%20introduces%20Gyrolab%20Generic%20Cyno%20ADA%20Kit%20Reagents%20to%20support%20pre-clinical%20immunogenicity%20assessment&#038;url=https:\/\/clinlabint.com\/gyros-protein-technologies-introduces-gyrolab-generic-cyno-ada-kit-reagents-to-support-pre-clinical-immunogenicity-assessment\/\" aria-hidden=\"false\" data-av_icon=\"\ue8fc\" data-av_iconfont=\"entypo-fontello\" title=\"\" data-avia-related-tooltip=\"Share on LinkedIn\" rel=\"noopener\"><span class='avia_hidden_link_text'>Share on LinkedIn<\/span><\/a><\/li><li class='av-share-link av-social-link-mail' ><a  aria-label=\"Share by Mail\" href='mailto:?subject=Gyros%20Protein%20Technologies%20introduces%20Gyrolab%20Generic%20Cyno%20ADA%20Kit%20Reagents%20to%20support%20pre-clinical%20immunogenicity%20assessment&#038;body=https:\/\/clinlabint.com\/gyros-protein-technologies-introduces-gyrolab-generic-cyno-ada-kit-reagents-to-support-pre-clinical-immunogenicity-assessment\/' aria-hidden='false' data-av_icon='\ue805' data-av_iconfont='entypo-fontello' title='' data-avia-related-tooltip='Share by Mail'><span class='avia_hidden_link_text'>Share by Mail<\/span><\/a><\/li><\/ul><\/div><\/div><\/p><\/div><div class=\"flex_column av_one_fifth  av-hide-on-mobile  flex_column_div av-zero-column-padding   avia-builder-el-10  el_after_av_three_fifth  avia-builder-el-last  \" style='border-radius:0px; '><section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><p style=\"text-align: center\"><\/p>\n<\/div><\/section><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ready-to-use kit expands range of bioanalysis kits, and enables generic detection of immune complexes in cyno samples<\/p>\n","protected":false},"author":3,"featured_media":19375,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[35],"tags":[],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/19374"}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=19374"}],"version-history":[{"count":2,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/19374\/revisions"}],"predecessor-version":[{"id":19378,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/19374\/revisions\/19378"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media\/19375"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=19374"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=19374"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=19374"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}